ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements

• Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients. (C) 2021 International Society for Heart and Lung Transplantation. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Nyckelord

lung transplantation

connective tissue diseases

biologic

disease-modifying anti rheumatic drugs

esophageal disorders

post-transplant medical and surgical management feedings

consensus

statement

gastroesophageal-reflux disease

familial mediterranean fever

active

rheumatoid-arthritis

primary raynauds-phenomenon

necrosis-factor

inhibitors

anti-tnf agents

systemic-sclerosis

liver-transplant

crohns-disease

postoperative complications

Cardiovascular System & Cardiology

Respiratory System

Surgery

Transplantation

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)